Aviptadil

Summary

Aviptadil (CHEMBL1981592) is a phase-3 clinical-stage protein; indicated across 3 conditions including severe acute respiratory syndrome and acute lung injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1981592
Name	Aviptadil
Type	Protein
Max phase	3

Also known as: Aviptadil, Aviptadil acetate, Samivirtm, Samiairtm, Samiviptm, Vip human vip, Zyesami, SID124893751, AVIPTADIL, HSDAVFTDNYTRLRKQMAVKKYLNSILN

Patent coverage: 248 distinct patent families (623 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 621 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Vasoactive intestinal polypeptide receptor 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
VIPR2	9.72	EC50	0.19	nM	CHEMBL_ACT_13878161

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
acute lung injury	2	MONDO:0015796	EFO:0004610
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04843761	PHASE3	COMPLETED	ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT06729606	PHASE3	COMPLETED	Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT04488081	PHASE2	ACTIVE_NOT_RECRUITING	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04536350	PHASE2	TERMINATED	Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
NCT04844580	PHASE2	COMPLETED	A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).